Brian A. Whiteman

Array ( [id] => 19847054 [patent_doc_number] => 20250092405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => METHODS OF TREATMENT OF SCN2A-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 18/885261 [patent_app_country] => US [patent_app_date] => 2024-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21910 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18885261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401297 [patent_doc_number] => 12491257 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates [patent_app_type] => utility [patent_app_number] => 18/755579 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 39 [patent_no_of_words] => 41761 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556809 [patent_doc_number] => 20240368601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => NCOVSIRNA DRUG FOR TARGETED DELIVERY SHRNA by RBD, SYNTHESIS METHOD, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/661524 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332865 [patent_doc_number] => 20240247295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => METHOD FOR PRECISELY PREPARING CIRCULAR RNA WITH ANABAENA INTRON SELF-CLEAVING RIBOZYME [patent_app_type] => utility [patent_app_number] => 18/430378 [patent_app_country] => US [patent_app_date] => 2024-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 354 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18430378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19497898 [patent_doc_number] => 20240336916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY [patent_app_type] => utility [patent_app_number] => 18/417565 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19512066 [patent_doc_number] => 20240343752 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM [patent_app_type] => utility [patent_app_number] => 18/417409 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19479793 [patent_doc_number] => 20240327835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME [patent_app_type] => utility [patent_app_number] => 18/417527 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19249082 [patent_doc_number] => 20240200069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => Synthetic Near-Threshold Translational Repressors [patent_app_type] => utility [patent_app_number] => 18/403466 [patent_app_country] => US [patent_app_date] => 2024-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12816 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18403466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586785 [patent_doc_number] => 20240384342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => MATERIALS AND METHODS FOR CONTROLLING GENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 18/403257 [patent_app_country] => US [patent_app_date] => 2024-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36654 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18403257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389782 [patent_doc_number] => 20240279652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES [patent_app_type] => utility [patent_app_number] => 18/509440 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067587 [patent_doc_number] => 20240102013 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors [patent_app_type] => utility [patent_app_number] => 18/485592 [patent_app_country] => US [patent_app_date] => 2023-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60849 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18485592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067586 [patent_doc_number] => 20240102012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => COMPOUNDS AND METHODS FOR MODULATING SCN2A [patent_app_type] => utility [patent_app_number] => 18/483663 [patent_app_country] => US [patent_app_date] => 2023-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18483663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067585 [patent_doc_number] => 20240102011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES [patent_app_type] => utility [patent_app_number] => 18/483333 [patent_app_country] => US [patent_app_date] => 2023-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18483333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332832 [patent_doc_number] => 20240247262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => CRISPR/CAS SYSTEM AND METHOD FOR GENOME EDITING AND MODULATING TRANSCRIPTION [patent_app_type] => utility [patent_app_number] => 18/464374 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18464374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402287 [patent_doc_number] => 20240285798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA [patent_app_type] => utility [patent_app_number] => 18/461021 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402287 [patent_doc_number] => 20240285798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA [patent_app_type] => utility [patent_app_number] => 18/461021 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034488 [patent_doc_number] => 20240084303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => AAV TREATMENT OF HUNTINGTON'S DISEASE [patent_app_type] => utility [patent_app_number] => 18/451147 [patent_app_country] => US [patent_app_date] => 2023-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18451147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19404032 [patent_doc_number] => 20240287543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => GLOBIN GENE THERAPY FOR TREATING HEMOGLOBINOPATHIES [patent_app_type] => utility [patent_app_number] => 18/355575 [patent_app_country] => US [patent_app_date] => 2023-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18355575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19203123 [patent_doc_number] => 20240175022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => RUNX1 Inhibition for Treatment of Proliferative Vitreoretinopathy and Conditions Associated with Epithelial to Mesenchymal Transition [patent_app_type] => utility [patent_app_number] => 18/351320 [patent_app_country] => US [patent_app_date] => 2023-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18351320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20402431 [patent_doc_number] => 12492401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/337495 [patent_app_country] => US [patent_app_date] => 2023-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 34 [patent_no_of_words] => 38308 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18337495 [rel_patent_id] =>[rel_patent_doc_number] =>)